P/E ratio for Hanmi Pharmaceutical (008930.KS)
P/E ratio as of April 2024 (TTM): 24.9
According to Hanmi Pharmaceutical 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 24.9048. At the end of 2022 the company had a P/E ratio of 32.4.
P/E ratio history for Hanmi Pharmaceutical from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 32.4 | -62.56% |
| 2021 | 86.6 | -61.77% |
| 2020 | 226 | 175.21% |
| 2019 | 82.3 | -69.97% |
| 2018 | 274 | 18.3% |
| 2017 | 232 | -46.54% |
| 2016 | 433 | 964.19% |
| 2015 | 40.7 | -0.38% |
| 2014 | 40.9 | -43.79% |
| 2013 | 72.7 | 129.2% |
| 2012 | 31.7 | -347.71% |
| 2011 | -12.8 | -209.23% |
| 2010 | 11.7 | 284.58% |
| 2009 | 3.05 | 67.9% |
| 2008 | 1.82 | -46.63% |
| 2007 | 3.40 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.